Cognition Therapeutics, Inc. (CGTX): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the companies dedicated to tackling age-related degenerative diseases? Cognition Therapeutics, Inc. (CGTX), a clinical-stage biopharmaceutical company founded in 2007, is focused on developing innovative therapeutics for disorders of the central nervous system and retina. With a lead product candidate, CT1812, in Phase 2 clinical trials, how is Cognition Therapeutics positioning itself in the competitive landscape, especially after reporting a net loss of $31.4 million in 2023? Keep reading to discover its history, ownership structure, mission, operational mechanisms, and revenue generation strategies.

Cognition Therapeutics, Inc. (CGTX) History

Cognition Therapeutics Founding Timeline

Year established

Cognition Therapeutics was founded in 2007.

Original location

The company is based in Pittsburgh, PA.

Founding team members

The founding team includes Dr. Hankinson, who contributed significantly to the early development of the company. Additional founders may be identified pending further validation of available sources.

Initial capital/funding

Details regarding the initial capital and funding are not available in the provided search results. Obtaining this information would require a dedicated financial database or direct inquiry to the company.

Cognition Therapeutics Evolution Milestones

Cognition Therapeutics Transformative Moments

Cognition Therapeutics has undergone several transformative moments that have shaped its trajectory:

• Clinical Trial Results: Positive Phase 2 clinical trial results for CT1812 in Alzheimer's disease significantly boosted the company's profile and potential.
• Financial Milestones: Successfully securing $25 million in Series C financing in 2020 and completing an IPO in 2021 marked critical steps in funding their research and development efforts.
• Pipeline Expansion: The FDA clearance of the IND application for CT1812 in Dravet syndrome and the development of CT2030 targeting TREM2 showcase the company's strategic expansion into new therapeutic areas and innovative approaches.

These moments reflect strategic decisions and scientific advancements that have propelled the company forward. You can also learn more about the company's goals at Mission Statement, Vision, & Core Values of Cognition Therapeutics, Inc. (CGTX).

Cognition Therapeutics, Inc. (CGTX) Ownership Structure

Understanding the ownership structure of Cognition Therapeutics, Inc. provides valuable insights into its governance and strategic direction, reflecting the distribution of control among various stakeholders.

Cognition Therapeutics, Inc. Current Status

Cognition Therapeutics, Inc. is a publicly traded company, meaning its shares are available for purchase on a stock exchange. As of 2024, it is listed on the NASDAQ under the ticker symbol CGTX.

Cognition Therapeutics, Inc. Ownership Breakdown

The ownership of Cognition Therapeutics, Inc. is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. The following table summarizes the ownership breakdown:

Cognition Therapeutics, Inc. Leadership

The leadership team at Cognition Therapeutics, Inc. is responsible for the company's strategic direction and operational execution. Key members of the leadership team as of April 2025 include:

• Lisa Ricciardi: President and Chief Executive Officer.
• Brent Fisher, M.D.: Chief Medical Officer.
• Kenneth S. Moch: Chairman of the Board.

For more information about the company's mission, vision, and core values, visit Mission Statement, Vision, & Core Values of Cognition Therapeutics, Inc. (CGTX).

Cognition Therapeutics, Inc. (CGTX) Mission and Values

Cognition Therapeutics aims to develop innovative therapies for age-related neurodegenerative diseases, focusing on improving the lives of patients suffering from conditions like Alzheimer's disease. The company is dedicated to scientific rigor and translating research into effective treatments.

Cognition Therapeutics' Core Purpose

Official mission statement

While a specific, stand-alone mission statement is not found in the provided context, Cognition Therapeutics' core purpose can be inferred from its activities and goals. The company focuses on:

• Developing innovative therapies for age-related neurodegenerative diseases.
• Targeting the sigma-2 receptor to address the underlying mechanisms of diseases like Alzheimer's.
• Striving to improve the lives of patients and their families affected by these conditions.

Vision statement

Similarly, a distinct vision statement is not explicitly available in the provided context. However, the vision of Cognition Therapeutics can be understood as:

• Becoming a leader in the development of disease-modifying treatments for neurodegenerative diseases.
• Creating therapies that can slow, halt, or reverse the progression of cognitive decline.
• Establishing a portfolio of novel compounds addressing unmet needs in the treatment of Alzheimer's and other related disorders.

Company slogan/tagline

Based on the information available, Cognition Therapeutics does not have a widely publicized official slogan or tagline. However, considering their focus, a possible implied tagline could be:

• 'Innovating for Cognitive Health.'
• 'Targeting the Future of Brain Health.'
• 'Advancing Therapies for Neurodegenerative Diseases.'

To delve deeper into the company's mission and vision, you can explore: Mission Statement, Vision, & Core Values of Cognition Therapeutics, Inc. (CGTX).

Cognition Therapeutics, Inc. (CGTX) How It Works

Cognition Therapeutics, Inc. focuses on developing innovative therapeutics targeting age-related degenerative diseases and disorders, particularly those affecting the brain, by addressing the underlying pathology of these conditions.

Cognition Therapeutics, Inc.'s Product/Service Portfolio

Cognition Therapeutics, Inc.'s Operational Framework

Cognition Therapeutics operates primarily as a research and development company, focusing on the discovery, development, and clinical testing of novel therapeutic candidates. Here’s a breakdown of their operational framework:

• Drug Development: Cognition's core activity revolves around identifying and developing drug candidates that can address the underlying causes of neurodegenerative and retinal diseases.
• Clinical Trials: A significant portion of their operations is dedicated to conducting clinical trials to evaluate the safety and efficacy of their drug candidates. These trials are essential for gathering data to support regulatory submissions and potential commercialization.
• Partnerships and Collaborations: Cognition collaborates with various academic institutions, research organizations, and pharmaceutical companies to advance their research and development efforts. These collaborations can provide access to additional expertise, resources, and funding.
• Intellectual Property: Cognition Therapeutics actively seeks to protect its innovations through patents and other intellectual property rights. This is crucial for maintaining a competitive advantage and attracting investment.

To gain more insights into the financial aspects, consider reading: Breaking Down Cognition Therapeutics, Inc. (CGTX) Financial Health: Key Insights for Investors

Cognition Therapeutics, Inc.'s Strategic Advantages

Cognition Therapeutics possesses several strategic advantages that contribute to its potential for success in the competitive biopharmaceutical industry:

• Targeting the Root Cause of Disease: Unlike some treatments that only address the symptoms of neurodegenerative diseases, Cognition's Elayta (CT1812) is designed to target and remove the toxic amyloid beta oligomers (AβOs) that are believed to be a primary driver of synaptic dysfunction and cognitive decline in Alzheimer's disease.
• Innovative Pipeline: Cognition's pipeline includes multiple drug candidates targeting different aspects of neurodegenerative and retinal diseases, which diversifies their risk and increases their chances of success.
• Experienced Management Team: Cognition's management team comprises experienced professionals with a proven track record in drug development, clinical research, and business development.
• Strong Intellectual Property Position: Cognition has secured patents and other intellectual property rights for its drug candidates and technologies, providing a competitive advantage and potential for long-term value creation.

Cognition Therapeutics, Inc. (CGTX) How It Makes Money

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for age-related degenerative diseases, particularly Alzheimer's disease; as of April 2025, it primarily generates revenue through research grants, collaborations, and potential future sales of its drug candidates if they receive regulatory approval.

Cognition Therapeutics, Inc.'s Revenue Breakdown

As a clinical-stage company, Cognition Therapeutics' revenue streams are subject to variability based on research progress and partnership agreements. The following table provides a hypothetical breakdown based on typical revenue sources for similar companies:

Cognition Therapeutics, Inc.'s Business Economics

The business economics of Cognition Therapeutics are characterized by substantial investment in research and development, typical for a biotechnology firm. Key aspects include:

• Drug Development Costs: Significant expenses are allocated to preclinical studies, clinical trials, and regulatory submissions.
• Intellectual Property: Protecting its drug candidates through patents is crucial for maintaining market exclusivity and attracting investment.
• Partnerships: Strategic alliances with larger pharmaceutical companies can provide funding and expertise, sharing the financial burden and risk.
• Market Opportunity: The increasing prevalence of Alzheimer's disease presents a large potential market, but success depends on clinical trial outcomes and regulatory approvals.

These elements shape the financial dynamics of Cognition Therapeutics, influencing its long-term viability and growth prospects.

Cognition Therapeutics, Inc.'s Financial Performance

Cognition Therapeutics' financial performance can be assessed through the following key points:

• Cash Runway: As of the end of 2023, Cognition Therapeutics reported having cash, cash equivalents, and marketable securities of $38.1 million. Management believes that this will be sufficient to fund operations into the second quarter of 2025.
• R&D Expenses: Research and development expenses for the year ended December 31, 2023 were $27.4 million, compared to $21.4 million for the year ended December 31, 2022.
• G&A Expenses: General and administrative expenses for the year ended December 31, 2023 were $9.8 million, compared to $9.7 million for the year ended December 31, 2022.
• Net Loss: Cognition Therapeutics reported a net loss of $36.5 million for the year ended December 31, 2023, compared to a net loss of $30.4 million for the year ended December 31, 2022.

For more insights into Cognition Therapeutics, Inc., check out: Exploring Cognition Therapeutics, Inc. (CGTX) Investor Profile: Who’s Buying and Why?

Cognition Therapeutics, Inc. (CGTX) Market Position & Future Outlook

Cognition Therapeutics is focused on developing innovative therapies for age-related degenerative diseases, particularly Alzheimer's disease. The company's future hinges on the successful clinical development and regulatory approval of its lead drug candidates, as well as its ability to secure funding and partnerships to advance its pipeline.

Competitive Landscape

Opportunities & Challenges

Industry Position

• Cognition Therapeutics is a clinical-stage biopharmaceutical company.
• The company focuses on developing therapeutics targeting the sigma-2 receptor to treat cognitive disorders.
• Their lead candidate, Elayta (CT1812), is an oral small molecule currently in Phase 2 clinical trials for Alzheimer's disease.
• Cognition's approach differs from many other companies in the Alzheimer's space, which primarily target amyloid plaques. Cognition aims to address the underlying synaptic dysfunction that occurs early in the disease process.
• The company is also exploring the potential of Elayta in other neurodegenerative diseases, such as dry age-related macular degeneration (AMD).

For more in-depth insights into investor behavior and company performance, explore: Exploring Cognition Therapeutics, Inc. (CGTX) Investor Profile: Who’s Buying and Why?